Search Results

PE-TRACT Trial of Catheter-Directed Therapy for Pulmonary Embolism Begins Enrollment

July 18, 2023—Akhilesh Sista, MD, who is Principal Investigator of the PE-TRACT randomized controlled trial (RCT), announced that the trial’s first patient has been enrolled by Bedros Taslakian, MD, and his team at NYU Langone Health in New York, New York.

Thrombolex Bashir Catheters Studied in Pivotal RESCUE Trial to Treat Acute PE

October 5, 2021—Thrombolex, Inc. announced the results from a prespecified interim analysis of the first 62 evaluable patients in the pivotal RESCUE trial of the company’s Bashir and Bashir S-B endovascular catheters in the treatment of acute pulmonary embolism (PE).

NIH Grant Funds RESCUE Trial of Thrombolex Bashir Catheter

July 2, 2020—Thrombolex Inc. has announced that it was awarded a $3 million Small Business Innovation Research (SBIR) Direct-to-Phase II grant from the National Heart, Lung and Blood Institute (NHLBI) section of the National Institutes of Health to fund the company’s pivotal RESCUE trial under an investigational device exemption.

Penumbra's Indigo Aspiration System Meets Primary Endpoints in EXTRACT-PE Trial

November 6, 2019—Penumbra, Inc. announced that the EXTRACT-PE trial met its primary endpoints, demonstrating the safety and efficacy of the company’s Indigo aspiration system for aspiration mechanical thrombectomy in patients with acute pulmonary embolism (PE).

Viz.ai’s Viz Recruit Platform Will Be Used to Expedite Patient Enrollment in PE-TRACT Trial

March 4, 2023—Viz.ai, a developer of artificial intelligence (AI)–powered disease detection and care coordination technology, announced that the company’s Viz Recruit platform will be used to optimize patient enrollment for the Pulmonary Embolism–Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial.

Thrombolex FIH Trial Supports Early Safety and Feasibility of the Bashir Catheter for Acute PE

March 5, 2020—Thrombolex, Inc., which is focused on endovascular therapies for the treatment of arterial and venous thromboembolic disorders, announced that its first-in-human (FIH) trial confirms the early safety and feasibility of the company's Bashir endovascular catheter for pharmacomechanical catheter-directed thrombolysis (CDT) in patients with acute pulmonary embolism (PE).

First Patient Enrolled in the RESCUE Trial of Thrombolex’s Bashir Catheter to Treat Acute Submassive PE

August 6, 2020—Thrombolex Inc. announced that it has enrolled the first patient in its pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary embolism (PE) using the Bashir endovascular catheter under an investigational device exemption (IDE) from the FDA.